Pharma major Lupin Limited (Lupin) announced the launch of Divalproex Sodium Extended-Release (ER) Tablets USP, 250 mg and 500 mg, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier. The product will be manufactured at Lupin's Nagpur facility in India.
Divalproex Sodium ER Tablets USP, 250 mg and 500 mg, is the generic equivalent of Depakote® ExtendedRelease (ER) Tablets, 250 mg and 500 mg, of AbbVie Inc., indicated for:
- Acute treatment of manic or mixed episodes associated with bipolar disorder, with or without psychotic features
- Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures
- Prophylaxis of migraine headaches
Divalproex Sodium Extended-Release (ER) Tablets USP (RLD: Depakote® ER) had annual sales of approximately USD 130 million in the U.S. (IQVIA MAT July 2020).
Shares of LUPIN LTD. was last trading in BSE at Rs.1040 as compared to the previous close of Rs. 1040.75. The total number of shares traded during the day was 170269 in over 7985 trades.
The stock hit an intraday high of Rs. 1053 and intraday low of 1017.35. The net turnover during the day was Rs. 176785219.